| Outcomes | No of Participants (studies) Follow up | Quality of the evidence (GRADE) | Relative effect (95% CI) | Anticipated absolute effects | |
|---|---|---|---|---|---|
| Risk with No treatment (diabetes) | Risk difference with Treatment (95% CI) | ||||
| All-cause mortality 140–159 mmHg |
6,334 (1 study) 4.4 years |
MODERATE1 due to imprecision |
RR 0.76 (0.64 to 0.9) | 90 per 1,000 | 22 fewer per 1,000 (from 9 fewer to 32 fewer) |
| Stroke 140–159 mmHg |
5,897 (1 study) 4.4 years |
MODERATE1 due to imprecision |
RR 0.8 (0.68 to 0.95) | 94 per 1,000 | 19 fewer per 1,000 (from 5 fewer to 30 fewer) |
| Heart failure 140–159 mmHg |
5,629 (1 study) 4.4 years |
MODERATE1 due to imprecision |
RR 0.78 (0.56 to 1.09) | 28 per 1,000 | 6 fewer per 1,000 (from 12 fewer to 2 more) |
Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.
From: Evidence review for initiating treatment
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.